LV10575B - Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs - Google Patents

Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs Download PDF

Info

Publication number
LV10575B
LV10575B LVP-93-310A LV930310A LV10575B LV 10575 B LV10575 B LV 10575B LV 930310 A LV930310 A LV 930310A LV 10575 B LV10575 B LV 10575B
Authority
LV
Latvia
Prior art keywords
alkyl
halogen
mono
atoms
bromine
Prior art date
Application number
LVP-93-310A
Other languages
English (en)
Latvian (lv)
Other versions
LV10575A (lv
Inventor
Bartlett Robert
Kammerer Friedrich-Johannes
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of LV10575A publication Critical patent/LV10575A/xx
Publication of LV10575B publication Critical patent/LV10575B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/40—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Air Conditioning Control Device (AREA)
  • Indole Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Medicinal Preparation (AREA)
LVP-93-310A 1990-05-18 1993-05-07 Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs LV10575B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4016178 1990-05-18
DE4017020 1990-05-26
DE4017043 1990-05-26
PCT/EP1990/001800 WO1991017748A1 (de) 1990-05-18 1990-10-24 Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung

Publications (2)

Publication Number Publication Date
LV10575A LV10575A (lv) 1995-04-20
LV10575B true LV10575B (en) 1996-04-20

Family

ID=27201216

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-310A LV10575B (en) 1990-05-18 1993-05-07 Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs

Country Status (28)

Country Link
US (2) US5494911A (cs)
EP (1) EP0527736B1 (cs)
JP (3) JP2995086B2 (cs)
KR (1) KR100188801B1 (cs)
CN (1) CN1051074C (cs)
AT (1) ATE151633T1 (cs)
AU (2) AU649421B2 (cs)
BR (1) BR9008022A (cs)
CA (1) CA2083179C (cs)
CY (1) CY2123B1 (cs)
CZ (4) CZ290474B6 (cs)
DE (1) DE59010701D1 (cs)
DK (1) DK0527736T3 (cs)
ES (1) ES2102367T3 (cs)
FI (1) FI105683B (cs)
GR (1) GR3023638T3 (cs)
HU (1) HU222234B1 (cs)
IE (1) IE911694A1 (cs)
IL (1) IL98163A (cs)
LV (1) LV10575B (cs)
NO (1) NO180118C (cs)
NZ (1) NZ238165A (cs)
PT (1) PT97689B (cs)
RU (2) RU2084223C1 (cs)
SK (3) SK281317B6 (cs)
TW (2) TW211558B (cs)
WO (1) WO1991017748A1 (cs)
YU (1) YU48765B (cs)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235563A (en) * 1989-10-13 1993-04-28 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical composition
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
GB9300083D0 (en) * 1993-01-05 1993-03-03 Roussel Lab Ltd Chemical compounds
EP0607777B1 (de) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Interleukin 8
DE59407414D1 (de) * 1993-01-08 1999-01-21 Hoechst Ag Verwendung von Leflunomid zur Hemmung von Tumornekrosefaktor alpha
ATE174218T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von interleukin 1 beta
ES2124799T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 alfa.
TW314467B (cs) * 1993-03-31 1997-09-01 Hoechst Ag
GB9313365D0 (en) * 1993-06-29 1993-08-11 Roussel Lab Ltd Chemical compounds
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
GB9322781D0 (en) * 1993-11-04 1993-12-22 Roussel Lab Ltd Aromatic amides
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
GB9520092D0 (en) * 1995-10-02 1995-12-06 Hoechst Roussel Ltd Chemical compounds
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
SI0795334T1 (sl) * 1996-03-12 2006-06-30 Sanofi Aventis Deutschland Predzdravila za zdravljenje tumorjev in vnetnih bolezni
DE19610955A1 (de) * 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
AU724549B2 (en) * 1996-09-04 2000-09-28 Pfizer Inc. Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF)
DE19702988A1 (de) * 1997-01-28 1998-07-30 Hoechst Ag Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
CA2302438A1 (en) * 1997-05-19 1998-11-26 Sugen, Inc. Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders
PT903345E (pt) * 1997-08-08 2001-01-31 Aventis Pharma Gmbh Forma cristalina de n-(4-trifluorometilfenil)-5-metil-isoxazolo-4-carboxamida
CA2309175A1 (en) * 1997-11-04 1999-05-14 Pfizer Products Inc. Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
HUP0102661A2 (hu) * 1998-04-17 2001-11-28 Parker Hughes Institute BTK-inhibitorok és a BTK-inhibitorok azonosítására szolgáló eljárások, valamint alkalmazásuk
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
SK8332002A3 (en) * 1999-12-16 2003-04-01 Teva Pharma Novel processes for making- and a new crystalline form of leflunomide
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US6723855B2 (en) * 2000-02-15 2004-04-20 Teva Pharmaceutical Industries Ltd. Method for synthesizing leflunomide
DE10133665A1 (de) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
US20030055263A1 (en) * 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
US6858637B2 (en) 2002-03-28 2005-02-22 Neurogen Corporation Substituted biaryl amides as C5a receptor modulators
WO2003082826A1 (en) * 2002-03-28 2003-10-09 Neurogen Corporation Substituted biaryl amides as c5a receptor modulators
JP2006505571A (ja) * 2002-10-15 2006-02-16 リゲル ファーマシューテイカルズ、インコーポレイテッド 置換されたインドール及びｈｃｖ阻害剤としてのその使用
RU2280464C2 (ru) * 2004-03-22 2006-07-27 Александр Иванович Петенко Способ получения сухого пробиотического препарата "бацелл"
ES2382383T3 (es) 2004-06-17 2012-06-07 Infinity Discovery, Inc. Compuestos y procedimientos para inhibir la interacción de proteínas Bcl con componentes de unión
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
DE102006014165A1 (de) * 2006-03-24 2007-09-27 Schebo Biotech Ag Neue Isooxazol-Derivate und deren Verwendungen
WO2008011453A2 (en) * 2006-07-20 2008-01-24 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
GEP20125379B (en) * 2007-05-03 2012-01-10 Pfizer Ltd 2 -pyridine carboxamide derivatives as sodium channel modulators
US20090076275A1 (en) * 2007-09-19 2009-03-19 David Robert Bolin Diacylglycerol acyltransferase inhibitors
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
CN104030987B (zh) 2009-04-02 2017-04-12 默克雪兰诺有限公司 二氢乳清酸脱氢酶抑制剂
EP2236505A1 (de) * 2009-04-03 2010-10-06 Bayer CropScience AG Acylierte Aminopyridine und - pyridazine als Insektizide
US20120171490A1 (en) 2009-07-09 2012-07-05 Alembic Pharmaceuticals Limited Novel polymorphic form of teriflunomide salts
BR112012024884A2 (pt) 2010-03-31 2016-10-18 Gilead Pharmasset Llc síntese estereosseletiva de ativos contendo fósforo
DK2608782T3 (en) 2010-08-24 2016-09-05 Algiax Pharmaceuticals Gmbh New use of leflunomide malononitrilamider
PT2632451T (pt) 2010-10-29 2017-12-14 Algiax Pharmaceuticals Gmbh Utilização de malononitrilamidas na dor neuropática
WO2012110911A1 (en) 2011-02-18 2012-08-23 Alembic Pharmaceuticals Limited Novel polymorphic form of teriflunomide
EP2685975A1 (en) 2011-03-17 2014-01-22 Algiax Pharmaceuticals GmbH Novel use of benzofuranylsulfonates
US20140038967A1 (en) 2011-03-17 2014-02-06 Algiax Pharmaceuticals Gmbh Novel use for imidazotriazinones
LT3019482T (lt) 2013-02-25 2018-11-26 Aurigene Discovery Technologies Limited Tripakeistieji benzotriazolo dariniai kaip dihidroorotato oksigenazės inhibitoriai
WO2015029063A2 (en) * 2013-08-30 2015-03-05 Msn Laboratories Private Limited Novel polymorph of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4-trifluoromethyl phenyl)-amide and process for the preparation thereof
EA201691057A1 (ru) 2013-11-22 2016-10-31 Джензим Корпорейшн Новые способы лечения нейродегенеративных заболеваний
LT3805233T (lt) 2014-01-13 2024-05-10 Aurigene Oncology Limited N-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo[4,5-b]piridin-6-il)-2-(2- metilpiridin-4-il)oksazol-karboksamido (r) ir (s) enantiomerai, kaip irak4 inhibitoriai, skirti vėžio gydymui
JP2017518348A (ja) * 2014-06-20 2017-07-06 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Ｉｒａｋ４阻害剤としての置換インダゾール化合物
CN105272882B (zh) * 2014-07-23 2019-05-31 欣凯医药化工中间体（上海）有限公司 一种环保简便制备泰瑞米特的方法
ES2870205T3 (es) * 2015-06-17 2021-10-26 Biocon Ltd Nuevo proceso para la preparación de teriflunomida
CA3053068A1 (en) 2017-02-24 2018-08-30 Merck Patent Gmbh 1, 4, 6-trisubstituted-2-alkyl-1h-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors
CA3056893A1 (en) 2017-03-31 2018-10-04 Aurigene Discovery Technologies Limited Compounds and compositions for treating hematological disorders
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
MA48459B1 (fr) 2017-04-24 2021-09-30 Aurigene Discovery Tech Ltd Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase
SI3704108T1 (sl) 2017-10-31 2024-07-31 Curis, Inc. Inhibitor irak4 v kombinaciji z inhibitorjem bcl-2 za uporabo pri zdravljenju raka
TR202022336A2 (tr) 2020-12-30 2022-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet comprising teriflunomide
IL307465A (en) 2021-04-08 2023-12-01 Curis Inc Combined therapies for cancer treatment
EP4162933A1 (en) 2021-10-08 2023-04-12 Algiax Pharmaceuticals GmbH Compound for treating non-alcoholic fatty liver disease and related diseases
CN117126078A (zh) * 2022-05-19 2023-11-28 四川大学 一类化合物及在治疗hDHODH介导的疾病中的用途
EP4382097A1 (en) 2022-11-25 2024-06-12 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet comprising teriflunomide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES448386A1 (es) * 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
DE2557003A1 (de) * 1975-12-18 1977-06-23 Hoechst Ag Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
DE2555789A1 (de) * 1975-12-11 1977-07-07 Hoechst Ag Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
DE2655009A1 (de) * 1976-12-04 1978-06-15 Hoechst Ag Isoxazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3405727A1 (de) * 1984-02-17 1985-08-22 Hoechst Ag, 6230 Frankfurt Isoxazol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
GB8619432D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
GB8619433D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
US4816467A (en) * 1987-01-09 1989-03-28 Farmitalia Carlo Erba S.R.L Heteroaryl 3-oxo-propanenitrile derivatives, pharmaceutical compositions and use

Also Published As

Publication number Publication date
RU2142937C1 (ru) 1999-12-20
CA2083179C (en) 2001-10-23
EP0527736A1 (de) 1993-02-24
IE911694A1 (en) 1991-11-20
AU662465B2 (en) 1995-08-31
JPH11343285A (ja) 1999-12-14
CZ290736B6 (cs) 2002-10-16
NO180118B (no) 1996-11-11
FI105683B (fi) 2000-09-29
AU649421B2 (en) 1994-05-26
YU88491A (sh) 1995-03-27
BR9008022A (pt) 1993-04-06
CA2083179A1 (en) 1991-11-19
YU48765B (sh) 1999-11-22
NO924433D0 (no) 1992-11-17
CZ290474B6 (cs) 2002-07-17
WO1991017748A1 (de) 1991-11-28
US5494911A (en) 1996-02-27
HUT64314A (en) 1993-12-28
HU9203619D0 (en) 1993-03-29
EP0527736B1 (de) 1997-04-16
GR3023638T3 (en) 1997-08-29
AU6546890A (en) 1991-12-10
SK281316B6 (sk) 2001-02-12
IL98163A0 (en) 1992-06-21
RU2084223C1 (ru) 1997-07-20
CN1056684A (zh) 1991-12-04
PT97689B (pt) 1998-09-30
TW211558B (cs) 1993-08-21
AU5799294A (en) 1994-07-07
CZ290737B6 (cs) 2002-10-16
JPH11322700A (ja) 1999-11-24
JP2995086B2 (ja) 1999-12-27
DK0527736T3 (da) 1997-10-20
JP3201747B2 (ja) 2001-08-27
ES2102367T3 (es) 1997-08-01
SK281318B6 (sk) 2001-02-12
US5532259A (en) 1996-07-02
SK281317B6 (sk) 2001-02-12
KR100188801B1 (ko) 1999-06-01
CY2123B1 (en) 2002-06-21
FI925211A0 (fi) 1992-11-17
TW205004B (cs) 1993-05-01
JPH05506425A (ja) 1993-09-22
HU222234B1 (hu) 2003-05-28
NZ238165A (en) 1994-08-26
CS145091A3 (en) 1992-01-15
JP3233610B2 (ja) 2001-11-26
NO180118C (no) 1997-02-19
ATE151633T1 (de) 1997-05-15
PT97689A (pt) 1992-02-28
CN1051074C (zh) 2000-04-05
RU94033835A (ru) 1996-04-20
FI925211L (fi) 1992-11-17
CZ290717B6 (cs) 2002-10-16
LV10575A (lv) 1995-04-20
NO924433L (no) 1992-11-17
DE59010701D1 (de) 1997-05-22
IL98163A (en) 1996-01-31

Similar Documents

Publication Publication Date Title
LV10575B (en) Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
DE60026822T2 (de) -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
AU670816B2 (en) N-cyano-N'-pyridylguanidines as serotonin antagonists
WO2015038778A1 (en) SUBSTITUTED UREA EIF2α KINASE ACTIVATORS
JP2008513508A (ja) 炎症及び免疫に関連する用途に用いる化合物
DE3889057T2 (de) Verbindungen für die Induktion der in vitro- und in vivo-Erzeugung von Cytokinen.
JPS6259264A (ja) ５−ピリミジンカルボキサミド、それらの製造法およびそれらからなる医薬組成物
EP0263506B1 (en) Anticonvulsant composition containing amino acid derivative and use of said amino acid derivative
US4371697A (en) 3-[1-(Hydroxymethyl)-2-phenylethyl]-N-[(phenylamino)-carbonyl]sydnone imine
US3803229A (en) Amides of 1-aminocyclopentane-carboxylic acid
US4289885A (en) 3-[2-(Dimethylamino)-2-phenylethyl]N-[phenylamino)carbonyl]sydnone imine, a new central nervous system stimulant
DE2600069A1 (de) Pharmazeutische praeparate
FI105680B (fi) Menetelmä terapeuttisesti käyttökelpoisten hydroksialkylideenisyaanietikkahappoamidien valmistamiseksi
BR112014017190B1 (pt) compostos com atividade antibacteriana, procedimento para a sua obtenção e composições farmacêuticas que fazem parte desses compostos
WO1982001184A1 (en) Sydnone imine derivatives,intermediates therefore and methods of preparation
LT3416B (en) Isoxazole-4-carboxamides, hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and method for the preparation of such drugs
JPS61210092A (ja) ジヒドロピリジン−５−ホスホン酸ジアミド誘導体